Erythromelalgia
Abstract
Abstract. Erythromelalgia is a rare syndrome characterized by the intermittent or, less commonly, by the permanent occurrence of extremely painful hyperperfused skin areas mainly located in the distal extremities. Primary erythromelalgia is nowadays considered to be a genetically determined neuropathic disorder affecting SCN9A, SCN10A, and SCN11A coding for NaV1.7, NaV1.8, and NaV1.9 neuronal sodium channels. Secondary forms might be associated with myeloproliferative disorders, connective tissue disease, cancer, infections, and poisoning. Between the pain episodes, the affected skin areas are usually asymptomatic, but there are patients with typical features of acrocyanosis and/or Raynaud’s phenomenon preceding or occurring in between the episodes of erythromelalgia. Diagnosis is made by ascertaining the typical clinical features. Thereafter, the differentiation between primary and secondary forms should be made. Genetic testing is recommended, especially in premature cases and in cases of family clustering in specialized genetic institutions after genetic counselling. Multimodal therapeutic intervention aims toward attenuation of pain and improvement of the patient’s quality of life. For this purpose, a wide variety of nonpharmacological approaches and pharmacological substances for topical and systemic use have been proposed, which are usually applied individually in a step-by-step approach. Prognosis mainly depends on the underlying condition and the ability of the patients and their relatives to cope with the disease.
Keywords: Erythromelalgia, erythermalgia, genetic pain syndrome, vascular acrosyndrome, chronic pain syndrome, small fibre polyneuropathy
Literature
. Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015;10:127.
. Erythromelalgia. UptoDate, update Dec 20,2016.
. Clinical lecture on certain painful affections of the feet. Philadelphia Medical Times. 1872;3:81–113.
. On a rare vaso-motor neurosis of the extremities and on the maladies with which it may occur. Am J Med Sci. 878;76:2–36.
. Erythermalgia (Erythromelalgia) of the extremities. A syndrome characterized by redness, heat, and pain. Am Heart J. 1938;16:175–88.
Behandlung der Erythromelalgie mit aktivem Weinkühler und Amitriptylin-Ketamin-Gel. Fallbericht mit aktueller Literaturübersicht. Phlebologie. 2007;36:151–5.
. Immersion foot associated with the overuse of ice, cold water, and fans: a distinctive clinical presentation complicating the syndrome of erythromelalgia. J Am Acad Dermatol. 2013;69:169–71.
. Three orphans one should know: red scalp, red ear and red scrotum syndrome. J Eur Acad Dermatol Venereol. 2016;30:e169–70.
. Erythema and burning pain in the vulva: a possible phenotype of erythromelalgia. Case Rep Med. 2011;2011;374167.
. Red Ear Syndrome. Curr Pain Headache Rep. 2016;20:19.
Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia. Arch Dermatol. 2003;139:1337–43.
. Functional vascular diseases: Raynaud’s syndrome, acrocyanosis and erythromelalgia. Vasa. 2010;39:33–41.
Clinical features and management of erythromelalgia: long term follow-up of 46 cases. Clin Exp Rheumatol. 2017;35:80–4.
. Skin perfusion in patients with erythromelalgia. Eur J Clin Invest. 1999;29:588–93.
. Impaired neurogenic control of skin perfusion in erythromelalgia. J Invest Dermatol. 2002;118:699–703.
. Erythromelalgia: a clinical study of 87 cases. J Intern Med. 1997;242:191–7.
Erythromelalgia: Incidence and clinical experience in a single centre in Sweden. Vasa. 2012;41:43–8.
. Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2009;23:13–5.
. Erythromelalgia? A clinical study of people who experience red, hot, painful feet in the community. Int J Vasc Med. 2013;2013:861–964.
Pediatric erythromelalgia: a retrospective review of 32 cases evaluated at Mayo Clinic over a 37-year period. J Am Acad Dermatol. 2012;66:416–23.
. Sex differences in the incidence of skin and skin-related diseases in Olmsted County, Minnesota, United States, and a comparison with other rates published worldwide. Int J Dermatol. 2016;55:939–55.
. Erythremalgia: New theories and new therapies. J Am Acad Dermatol. 2000;43:841–7.
. Cellular hyper-excitability caused by mutations that alter the activation process of voltage-gated sodium channels. Front Physiol. 2015;6(45):1–7.
. Painful and painless channelopathies. Lancet Neurol. 2014;13:587–99.
Natural history of erythromelalgia. Arch Dermatol. 2000;136:330–6.
Erythromelalgia in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2017;58:715–7.
Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985;102:466–71.
. Erythromelalgia as a paraneoplastic syndrome in a patient with abdominal cancer. Acta Derm Venereol. 1999;79:394.
Facial erythromelalgia: a rare entity to consider in the differential diagnosis of connective tissue diseases. J Am Acad Dermatol. 2014;71:e250–1.
. Erythromelalgia in a patient with AIDS. J Eur Acad Dermatol Venereol. 2000;14:498–500.
Erythromelalgia associated with Clitocybe acromelalga intoxication. Clin Toxicol (Phila). 2013;51:451–4.
Verapamil-induced erythermalgia. Neth J Med. 2007;65:349–51.
Early detection of an epidemic erythromelalgia outbreak using Baidu search data. Sci Rep. 2015;5:12649.
A large temperature fluctuation may trigger an epidemic erythromelalgia outbreak in China. Sci Rep. 2015;5:9525.
. Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations. Curr Neurol Neurosci Rep. 2012;12:76–83.
. Erythromelalgia – pathophysiological and therapeutic aspects. A preliminalry report. J Oslo City Hosp. 1987;37:9–12.
Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia. J Invest Dermatol. 2000;114:643–6.
Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism. J Invest Dermatol. 2002;119:949–53.
Davis JS 4th. Erythromelalgia as a form of neuropathy. Arch Dermatol. 1992;128:1654–5.
. Autonomic innervation of the skin in primary erythermalgia. Arch Dermatol. 1983;119:65–71.
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41:171–4.
A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J Biol Chem. 1997;272:14805–9.
Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci USA. 1997;94:1527–32.
Structure and functional expression of a new member of the tetrodotoxin-sensitive voltageactivated sodium channel family from human neuroendocrine cells. EMBO J. 1995;14:1084–90.
SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol. 2005;124:1333–8.
. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005;128:184754.
Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol. 2006;59:553–8.
Genetic heterogeneity and exclusion of a modifying locus at 2q in a family with autosomal dominant primary erythermalgia. Br J Dermatol. 2005;153:174–7.
Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia. Neuromolecular Med. 2013;15:265–78.
Inherited pain: sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation. J Biol Chem. 2014;289:1971–80.
Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations. J Neurosci. 2015;35:7674–81.
. Nonlinear effects of hyperpolarizing shifts in activation of mutant Na(v)1.7 channels on resting membrane potential. J Neurophysiol. 2017;117:1702–12.
Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7. Mol Pain. 2011;7:92.
Painful neuropathies: the emerging role of sodium channelopathies. J Peripher Nerv Syst. 2014;19:53–65.
SCN10A Mutation in a Patient with Erythromelalgia Enhances C-Fiber Activity Dependent Slowing. PLoS One. 2016;11:e0161789.
Pathological nociceptors in two patients with erythromelalgia-like symptoms and rare genetic Nav1.9 variants. Brain Behav. 2016;6:e00528.
Nav1.7-A1632G Mutation from a Family with Inherited Erythromelalgia: Enhanced Firing of Dorsal Root Ganglia Neurons Evoked by Thermal Stimuli. J Neurosci. 2016;36:7511–22.
Temperature dependence of erythromelalgia mutation L858F in sodium channel Nav1.7. Mol Pain. 2007 Jan;3:3.
Nonspecific capillary proliferation and vasculopathy indicate skin hypoxia in erythromelalgia. Arch Dermatol. 2011;147:309–14.
Epidermal nerve fiber quantification in patients with erythromelalgia. JAMA Dermatol. 2016 Dec 7. doi: 10.1001/jamadermatol.2016.4404.
Thermoregulatory sweat testing in patients with erythromelalgia. Arch Dermatol. 2006;142:1583–8.
Autonomic dysfunction in SCN9A-associated primary erythromelalgia. Clin Auton Res. 2013;23:105–7.
Neurophysiologic and vascular studies in erythromelalgia: a retrospective analysis. J Clin Neuromuscul Dis. 1999;1:57–63.
. Erythromelalgia. Current Treatment Options in Cardiovascular Medicine. 2006;8:152–65.
. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. 2005;141:1320–1.
Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. J Drugs Dermatol. 2013;12:308–10.
Topically Applied Midodrine, 0.2 %, an α1-Agonist, for the Treatment of Erythromelalgia. JAMA Dermatol. 2015;151:1025–6.
Response of primary erythromelalgia to pregabalin therapy. J Clin Rheumatol. 2013;19:284–5.
Successful treatment of adult-onset erythromelalgia with steroid pulse and pregabalin. Case Rep Dermatol. 2012;4:242–6.
Erythromelalgia: Identification of a corticosteroid-responsive subset. J Am Acad Dermatol. 2017;76:506–11.
Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV1.7 sodium channels. Br J Pharmacol. 2014;171:4455–63.
Erythromelagia: a rare and hard-to-treat condition: a 9-year-old boy responsive to intravenous lidocaine and oral mexilitene. Pain Med. 2013;14:311–2.
Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics. 2005;115:e504–7.
. Prostacyclin reduces symptoms and sympathetic dysfunction in erythromelalgia in a double-blind randomized pilot study. Acta Derm Venereol. 2003;83:442–4.
The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia - a double-blind, crossover, placebo-compared study. J Invest Dermatol. 2004;122:587–93.
. Intractable erythromelalgia of the lower extremities successfully treated with lumbar sympathetic block. J Am Acad Dermatol. 2013;69:e270–2.
. Resolution of refractory symptoms of secondary erythermalgia with intermittent epidural bupivacaine. Reg Anesth Pain Med. 2001;26:488–90.
. Spinal Cord Stimulation for Treatment of Neuropathic Pain Associated with Erythromelalgia. Reg Anesth Pain Med. 2016;41:619–20.
Dual Effect of Ziconotide in primary erythromelalgia. Case Rep Med. 2015;2015:592170.
. Successful treatment of erythromelalgia with intrathecal hydromorphone and clonidine. Clin J Pain. 2000;16:310–3.
Natural history of erythromelalgia. Arch Dermatol. 2000;136:330–6.
Clinical features and management of erythromelalgia: long term follow-up of 46 cases. Clin Exp Rheumatol. 2017;35:80–4.
